Human Papillomavirus Vaccine Market to be Supported by Growing Prevalence of Human Papillomavirus related Diseases through 2028
Growing prevalence of HPV-related diseases to drive the human
papillomavirus vaccine market in the forecast period, 2024-2028.
According to TechSci Research report, “Human
Papillomavirus Vaccine Market - Global Industry Size, Share, Trends, Opportunity,
and Forecast, 2018-2028”, the global human papillomavirus vaccine market is
anticipated to grow at a significant rate in the forecast period, 2024-2028. The
rise in research and development activities, growing technological advancements,
large number of women suffering from cervical cancer, among others, are some of
the factors that are expected to drive the growth of global human
papillomavirus vaccine market. Also, the rise in adoption of advanced
technology to significantly improve the ability to facilitate communication,
access information, and enhance efficiency is surging the growth of the market.
For instance, in 2021, Becton, Dickinson, and Company, a prominent medical
technology company, introduced the first CE-marked assay for HPV screening from
at-home self-collected vaginal samples. This enables laboratories to process
self-collected samples via a Becton, Dickinson, and Company diluent tube
However, the limited availability of the vaccine,
low affordability, and high cost of the vaccines for common people are likely to
hamper the growth of the global human papillomavirus vaccine market. Stringent
regulatory approval scenario further restricts the market growth.
Browse over XX market
data Figures spread through XX Pages and an in-depth TOC on "Human Papillomavirus Vaccine Market"
The global human
papillomavirus vaccine market is segmented into valence, disease indication,
distribution channel, region, and company.
Based on valence, the market
is divided into bivalent, quadrivalent, nonvalent, and others. The tetravalent
sub-segment is expected to hold the largest market share as this type of
vaccine protects against
HPV types 6, 11, 16, and 18.
Based on disease indication,
the market is divided into cervical cancer, anal cancer, vaginal cancer, penile
cancer, vulvar cancer, and others. The
cervical cancer segment is expected to witness largest market share. This is
attributed to the rise in number of cases of cervical cancer among the
population, which propels the demand for cervical cancer human papillomavirus vaccine.
Based on distribution
channel, the market is segmented into hospitals & clinics, governmental
& non-governmental organizations, public & private alliances, and
others. The public & private alliances segment is anticipated to grow
during the forecast period. This is attributed to the rise in initiatives like
vaccinating people in developing countries. Several organizations and
institutions, such as GAVI, the vaccine alliance are also trying to improve
vaccine use in low-mid-countries by providing low-cost vaccines.
Major companies operating
in global human papillomavirus vaccine market are:
- Serum Institute of India Pvt. Ltd.
- GlaxoSmithKline Plc.
- Johnson & Johnson
- Merck & Co., Inc.
- AstraZeneca Plc
- Novartis AG
- Inovio Pharmaceuticals, Inc.
- Xenetic Biosciences, Inc.
- Sanofi SA
- Bharat Biotech International Limited
Download Free Sample Report
Customers can also
request for 10% free customization on this report.
“Asia-Pacific region dominated the
market in 2022 and is expected to maintain its dominance in the coming years
due to increasing cases of cervical cancer. The strong desire to overcome the
burden of human papillomavirus infections, increasing number of clinical trials
related to the development of human papillomavirus vaccine and an expansion of key
players operating in the market in the region is expected to support the market
growth through 2028.” said Mr. Karan Chechi, Research Director with
TechSci Research, a research based global management consulting firm.
“Human Papillomavirus Vaccine
Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028, Segmented By Valence
(Bivalent, Quadrivalent, Nonvalent, Others), By Disease Indication (Cervical
Cancer, Anal Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, Others), By
Distribution Channel (Hospitals & Clinics, Governmental &
Non-Governmental Organizations, Public & Private Alliances, Others), By
Region, and Competition”, has evaluated the future growth potential of global human
papillomavirus vaccine market and provides statistics & information on
market size, structure, and future market growth. The report intends to provide
cutting-edge market intelligence and help decision makers take sound investment
decisions. Besides, the report also identifies and analyzes the emerging trends
along with essential drivers, challenges, and opportunities in global human
papillomavirus vaccine market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com